Major infections in newly diagnosed systemic lupus erythematosus: an inception cohort study. Issue 1 (30th August 2022)

• Record Type: Journal Article
• Authors: Wang, Haiting; Zhou, Yuhong; Yu, Liqin; Wu, Wanlong; Zhao, Liling; Geng, Shikai; Sun, Fangfang; Zhang, Danting; Shen, Nan; Chen, Yi; Ye, Shuang
• Is Part Of: Lupus science & medicine. Volume 9:Issue 1(2022)
• Publication Date: 2022-08-30
• Subjects: systemic lupus erythematosus -- outcome assessment, health care -- therapeutics; Systemic lupus erythematosus -- Periodicals; 616.772005
• DOI: 10.1136/lupus-2022-000725
• Languages: English
• ISSNs: 2398-8851

Abstract

Abstract : Objective: To evaluate the risk of major infections and the relationship between major infections and mortality in patients with newly diagnosed SLE. Methods: A newly diagnosed (<3 months) hospitalised Systemic Lupus Inception Cohort (hSLIC) in our centre during 1 January 2013 and 1 November 2020 was established. All patients were followed up for at least 1 year or until death. Patient baseline characteristics were collected. Major infection events were recorded during follow-up, which were defined as microbiological/clinical-based diagnosis treated with intravenous antimicrobials. The cohort was further divided into a training set and a testing set. Independent predictors of major infections were identified using multivariable logistic regression analysis. Kaplan-Meier survival analyses were conducted. Results: Among the 494 patients enrolled in the hSLIC cohort, there were 69 documented episodes of major infections during the first year of follow-up in 67 (14%) patients. The major infection events predominantly occurred within the first 4 months since enrolment (94%, 65/69) and were associated with all-cause mortality. After adjustments for glucocorticoid and immunosuppressant exposure, a prediction model based on SLE Disease Activity Index >10, peripheral lymphocyte count <0.8×10 9 /L and serum creatinine >104 µmol/L was established to identify patients at low risk (3%–5%) or high risk (37%–39%) of major infections within the first 4 months. Conclusions: Newly onset active SLE is susceptible to major infections, which is probably due to underlying profound immune disturbance. Identifying high-risk patients using an appropriate prediction tool might lead to better tailored management and better outcome.